Clinical Trials Browser

Active not recruiting × Urogenital Neoplasms × 90 days × Clear all

NCT02496208 2026-03-18

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT07038369 2026-03-17

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Phase 1 Active not recruiting

BreastGenitourinaryGynecologic

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Phase 2 Active not recruiting

EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

NCT01505400 2026-01-08

IMPACT

Active not recruiting

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Unknown Primary, Urogenital Neoplasms, Colorectal Neoplasms

NCT05902520 2026-01-08

ACT

Phase 1 Active not recruiting

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Lung Neoplasms, Melanoma, Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

NCT03794635 2026-01-07

An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer

Phase NA Active not recruiting

Lymphoma, Neoplasm Metastasis, Urogenital Neoplasms

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

Phase 1/2 Active not recruiting

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

NCT06229366 2025-12-22

ACCEL

Phase 1 Active not recruiting

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms